The Predictive Value of Early In-Treatment <sup>18</sup>F-FDG PET/CT Response to Chemotherapy in Combination with Bevacizumab in Advanced Nonsquamous Non-Small Cell Lung Cancer.
View/ Open
Date
2017-08ICR Author
Author
Usmanij, EA
Natroshvili, T
Timmer-Bonte, JNH
Oyen, WJG
van der Drift, MA
Bussink, J
Geus-Oei, L-FD
Type
Journal Article
Metadata
Show full item recordAbstract
18 F-FDG PET/CT is potentially applicable to predict response to chemotherapy in combination with bevacizumab in patients with advanced non-small cell lung cancer (NSCLC). Methods: In 25 patients with advanced nonsquamous NSCLC, 18 F-FDG PET/CT was performed before treatment and after 2 wk, at the end of the second week of first cycle carboplatin-paclitaxel and bevacizumab (CPB) treatment. Patients received up to a total of 4 cycles of CPB treatment. Maintenance treatment with bevacizumab monotherapy was continued until progressive disease without significant treatment-related toxicities of first-line treatment. In the case of progressive disease, bevacizumab was combined with erlotinib. SUV corrected for lean body mass (SUL and SUL peak ) were obtained. PERCIST were used for response evaluation. These semiquantitative parameters were correlated with progression-free survival and overall survival (OS). Results: Metabolic response, defined by a significant reduction in SUL peak of 30% or more after 2 wk of CPB, was predictive of progression-free survival and OS. For partial metabolic responders ( n = 19), the median OS was 22.8 mo. One-year and 2-y OS were 79% and 47%, respectively. Nonmetabolic responders ( n = 6) (stable metabolic disease or progressive disease) showed a median OS of 4.4 mo (1-y and 2-y OS was 33% and 0%, respectively) ( P < 0.001). Conclusion: 18 F-FDG PET/CT after 1 treatment cycle is predictive of outcome to first-line chemotherapy with bevacizumab in patients with advanced nonsquamous NSCLC. This enables identification of patients at risk of treatment failure, permitting treatment alternatives such as early switch to a different therapy.
Collections
Subject
Humans
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Fluorodeoxyglucose F18
Follow-Up Studies
Predictive Value of Tests
Time Factors
Adult
Aged
Aged, 80 and over
Middle Aged
Female
Male
Bevacizumab
Positron Emission Tomography Computed Tomography
Research team
Translational Molecular Imaging
Language
eng
Date accepted
2017-01-31
License start date
2017-08
Citation
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2017, 58 (8), pp. 1243 - 1248